PL414021A1 - Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours - Google Patents

Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours

Info

Publication number
PL414021A1
PL414021A1 PL414021A PL41402115A PL414021A1 PL 414021 A1 PL414021 A1 PL 414021A1 PL 414021 A PL414021 A PL 414021A PL 41402115 A PL41402115 A PL 41402115A PL 414021 A1 PL414021 A1 PL 414021A1
Authority
PL
Poland
Prior art keywords
treatment
pharmaceutical formulation
dexorubicin
tumours
formulation containing
Prior art date
Application number
PL414021A
Other languages
Polish (pl)
Other versions
PL229503B1 (en
Inventor
Maciej Mazur
Pamela Krug
Katarzyna Wiktorska
Zdzisław Chilmończyk
Lidia Śliwka
Original Assignee
Uniwersytet Warszawski
Narodowy Instytut Leków
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Warszawski, Narodowy Instytut Leków filed Critical Uniwersytet Warszawski
Priority to PL414021A priority Critical patent/PL229503B1/en
Publication of PL414021A1 publication Critical patent/PL414021A1/en
Publication of PL229503B1 publication Critical patent/PL229503B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest formulacja farmaceutyczna o właściwościach przeciwnowotworowych zawierająca doksorubicynę i co najmniej jeden izotiocyjanian jako substancję wzmacniającą działanie doksorubicyny do zastosowania w leczeniu nowotworu, przy czym doksorubicyna i co najmniej jeden izotiocyjanian umieszczone są w nośniku lipidowym.The subject of the application is a pharmaceutical formulation with anti-cancer properties comprising doxorubicin and at least one isothiocyanate as a substance enhancing the action of doxorubicin for use in the treatment of cancer, wherein doxorubicin and at least one isothiocyanate are placed in a lipid carrier.

PL414021A 2015-09-21 2015-09-21 Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours PL229503B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL414021A PL229503B1 (en) 2015-09-21 2015-09-21 Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL414021A PL229503B1 (en) 2015-09-21 2015-09-21 Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours

Publications (2)

Publication Number Publication Date
PL414021A1 true PL414021A1 (en) 2017-03-27
PL229503B1 PL229503B1 (en) 2018-07-31

Family

ID=58360332

Family Applications (1)

Application Number Title Priority Date Filing Date
PL414021A PL229503B1 (en) 2015-09-21 2015-09-21 Pharmaceutical formulation containing isocyanates and dexorubicin to be applied in treatment of tumours

Country Status (1)

Country Link
PL (1) PL229503B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL238526B1 (en) * 2018-09-04 2021-08-30 Narodowy Inst Lekow Combination of isothiocyanates with organic selen compounds in drug carriers as a new pharmaceutical with antitumor activity
PL241189B1 (en) * 2018-09-27 2022-08-22 Narodowy Inst Lekow Pharmaceutical formulation containing selenitetrigliceride and cytostatic for use in cancer treatment

Also Published As

Publication number Publication date
PL229503B1 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CL2016001609A1 (en) Pharmaceutical compositions comprising azd9291.
CL2016000807A1 (en) Amino heteroaryl benzamides as kinase inhibitors.
MY197324A (en) Adenovirus armed with bispecific t cell activator
ECSP16075472A (en) CONJUGATES OF ANTI-DROSOPHILA SIMILAR ANTIBODIES TO DELTA 3 (ANTI-DLL3) AND DRUGS FOR USE IN THE TREATMENT OF MELANOMA
SV2017005461A (en) BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO
CO2017001994A2 (en) Active compounds towards bromodomains
CL2015001985A1 (en) Thiazolcarboxamides and pyridinecarboxamide compounds, pim kinase inhibitors.
SV2017005355A (en) CARRIER-ANTIBODY COMPOSITIONS AND METHODS TO PERFORM AND USE THEM
MX2017013613A (en) Cancer neoepitopes.
CL2014001865A1 (en) Phosphate derived compounds; preparation procedure; pharmaceutical compositions containing them and use in the treatment of cancer.
ECSP15026557A (en) COMPOUNDS AND THEIR METHODS OF USE
CL2015002194A1 (en) Erk inhibitors and their uses
CL2016002516A1 (en) "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct
BR112015011756A2 (en) glutamase inhibitors and methods of use
CL2018000222A1 (en) New combination for use in cancer treatment
CL2014001829A1 (en) Compounds derived from indolizine; preparation procedure; pharmaceutical compositions containing them and use in the treatment of cancer.
DOP2015000108A (en) PIRROLOPIRIMIDINE COMPOUNDS AS QUINASE INHIBITORS
BR112015019064A2 (en) melanoma treatment methods
CL2014003465A1 (en) Antibody that binds to the dimeric human epidermal growth factor receptor (hegfr); pharmaceutical composition comprising it; and use to treat cancer.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CL2013000018A1 (en) Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others.
BR112015016681A8 (en) use of nanoparticles comprising paclitaxel and an albumin, kit, drug, composition and unit dosage form for the treatment of pancreatic cancer
MX2015009106A (en) Solid solution compositions and use in severe pain.
CL2018000963A1 (en) Cosmetic that has probiotic bacteria
CL2015003343A1 (en) Pharmaceutical composition comprising a modified therapeutic agent based on hemoglobin, for the treatment to treat cancer, and diagnostic images.